Reshape Lifesciences Inc (NAS:RSLS)
$ 5.915 -0.105 (-1.74%) Market Cap: 3.00 Mil Enterprise Value: 2.21 Mil PE Ratio: 0 PB Ratio: 0.99 GF Score: 64/100

Q3 2022 ReShape Lifesciences Inc Earnings Call Transcript

Nov 14, 2022 / 01:00PM GMT
Release Date Price: $696 (+3.18%)
Operator

Good morning, and thank you for joining the ReShape Lifesciences Second Quarter 2022 Conference Call. I would now like to turn the call over to Paula Schwartz from Rx Communications. Please go ahead.

Paula Schwartz
Rx Communications Group LLC - MD

Good morning, and thank you for joining the ReShape Lifesciences Third Quarter 2022 Earnings Call. I'm pleased to be joined by Paul Hickey, President and Chief Executive Officer of ReShape Life Sciences; and Thomas Stankovich, Chief Financial Officer. Paul will provide an overview and update on the company's activities, and Tom will review the final results for the quarter. He will then turn the call back over to Paul for some closing remarks, after which we will open up the call to a question-and-answer session.

As a reminder, this conference call as well as ReShape Lifesciences' SEC filings and website including the Investor Information section of the website, contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot